Stay updated with breaking news from Catalyze Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens -; specifically for adverse events arising from atherosclerosis.
San Francisco, CA — July 12, 2023 – Schneider Electric, the leader in the digital transformation of energy management and automation, today launched Catalyze, a new partnership program aimed at accelerating access to renewable energy across the global semiconductor value chain. Unveiled during SEMICON West 2023, Catalyze is a first-of-its kind program of collaboration among key semiconductor…
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis Print Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release. A recent study by medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain reli...